Keratoacanthoma - I-Keratoacanthoma
☆ AI Dermatology — Free Service
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Okuvamile i-Keratoacanthoma (Keratoacanthoma).
relevance score : -100.0%
ReferencesI‑Keratoacanthoma (KA) iyithumba lesikhumba elivamile elaziwa ngokukhula ngokushesha nokuhla ngokushesha. Ngokuvamile, ivela kwabesilisa asebekhulile abanesikhumba esikhanyayo nabathintekile ukulimala kwelanga. Nakuba ukususa ngohlelo lokuhlinza, njengokuhlinzwa noma ukuhlinzwa kwe‑Mohs micrographic, kuyindlela evamile yokwelapha, kukhona nezinye izindlela zokwelapha ezitholakalayo.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
I-Keratoacanthoma (KA) iyithumba eliphansi eliqala ezindaweni ezithile esikhumbeni futhi libukeka lifana ne-squamous cell carcinoma (SCC) ngaphansi kwesibonakaliso. Kunenkulumompikiswano eqhubekayo mayelana nokuthi i-KA kufanele yini ifakwe kuhlobo lwe-SCC oluhlaselayo.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) wuhlobo lwesibili oluvame kakhulu lomdlavuza kubantu, ikakhulukazi kubantu abadala. Ukuhlinzwa kuvame ukusetshenziselwa ukwelapha i‑cSCC, kodwa kwezinye iziguli ezingakwazi ukuhlinzwa noma ezikhetha ukungakwenzi, ezinye izinketho ezifana nokwelashwa kwe‑intralesional zingacatshangelwa. Ukwelashwa kwendabuko kwe‑intralesional (methotrexate noma 5‑fluorouracil) sekusetshenzisiwe, kodwa kusekhona ucwaningo oluqhubekayo mayelana nezindlela ezintsha ezifana ne‑intralesional immunotherapy kanye ne‑oncolytic virotherapy. Lapha, sizobheka izindlela ezihlukene zokwelapha i‑cSCC, kusukela ezindleleni zakudala kuya kumasu aphambili.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Ngaphansi kwe‑microscope, i‑keratoacanthoma (keratoacanthoma) ifana kakhulu ne‑squamous cell carcinoma. Nakuba ezinye izazi zezifo zihlukanisa i‑keratoacanthoma (keratoacanthoma) njengento ehlukile futhi hhayi isifo esibulalayo, cishe u‑6 % wezokwelapha kanye ne‑histological i‑keratoacanthoma (keratoacanthoma) uyathuthukela kumdlavuza we‑squamous cell ohlaselayo nonolaka.
○ Ukuxilongwa Nokwelashwa
#Dermoscopy
#Skin biopsy